Meeting
2018 ASCO Annual Meeting
An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).
Authors
Karim Fizazi
Gustave Roussy, Villejuif, France
Karim Fizazi , Charles G. Drake , David R. Shaffer , Russell Pachynski , Fred Saad , Marika Ciprotti , George Kong , Charles J. Ryan , Daniel Peter Petrylak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03338790
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS3126)
DOI
10.1200/JCO.2018.36.15_suppl.TPS3126
Abstract #
TPS3126
Poster Bd #
327b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).
First Author: Russell Kent Pachynski
Poster
2022 ASCO Gastrointestinal Cancers Symposium
CA209-8YD: A phase I/II trial of rucaparib in combination with ramucirumab with or without nivolumab in previously treated advanced gastroesophageal adenocarcinoma (GEA) (RiME).
First Author: Anwaar Saeed
Poster
2021 ASCO Annual Meeting
Complementary detection of genomic alterations in metastatic castration‑resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.
First Author: Mark Sausen
Poster
2020 Genitourinary Cancers Symposium
A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer.
First Author: Akash Patnaik